BSE filing, NSE: INDORAMA. Summary written from the filing by ALFA Finder's alert engine.
Indo Rama Synthetics (India) Ltd: key numbers
- Share price
- ₹74.54
- Market cap
- ₹1,946 Cr
- Revenue (annual)
- ₹4,910 Cr
- Net profit (annual)
- ₹150.2 Cr
- P/E (TTM)
- 9.2×Sector 50.4×
- Promoter holding
- 75.00%+0.16% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo Rama Synthetics (India) Ltd
All →Indo Rama Synthetics (India) Earnings Call Transcript: Key Takeaways
Indo Rama is stabilizing after massive capacity expansions, showing significant profit recovery as margins expand.
- Call
- Guides 15% growth
Indo Rama Synthetics (India) Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹1,340.6 Cr (+9.8%), EBITDA ₹117.7 Cr (+46%, 8.8% margin), PAT ₹74.1 Cr (+202%). H1 revenue down ~10%; ₹200 Cr specialty expansion planned.
Indo Rama Synthetics (India) Capacity Expansion: ₹200 Cr Investment
Indo Rama Synthetics approved a Rs. 200 Crore expansion plan for speciality filament and fibre production. The project at Nagpur is expected to be operational within 12-18 months.
- Value
- ₹200.0 Cr
- Execution
- 12-18 months
Indo Rama Synthetics (India) Q2 FY27 Results: Net Profit ₹74.1 Cr, Up 201.2% YoY
Indo Rama Synthetics (India) Ltd reported revenue from operations of ₹1,341 Cr (+9.8% YoY) and net profit of ₹74.1 Cr (+201.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.1 Cr · +201.2% YoY
Indo Rama Synthetics (India) Board Meeting Date
Indo Rama Synthetics will hold a board meeting on 16 October 2026 to consider unaudited standalone and consolidated financial results for the quarter ended September 2026.
Indo Rama Synthetics (India) Other Announcement
Indo Rama Synthetics (India) Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required under SEBI regulations.
Other results update announcements
All →UFO Moviez India Results Update
UFO Moviez reported Q2 FY27 consolidated revenue up 17% to ₹1,299 mn, with PAT at ₹64 mn. H1 FY27 revenue rose 10% to ₹2,417 mn.
Global Health Results Update
Global Health reported Q2 FY27 revenue of INR 14,690 million, up 33.6%, and PAT of INR 2,191 million, up 38.3%. Board approved a 500-bed Ghaziabad hospital.
BLS International Services Results Update
BLS International reported record Q2 FY27 revenue of Rs 973 Crore, up 32% year-on-year. H1 FY27 revenue rose 28.7% to Rs 1,863 Crore.
Cosmo First Results Update
Cosmo First released Q2 FY27 consolidated results via press release, showing EBITDA and PAT growth. Net debt was reduced while B2B and consumer businesses scaled up.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.